Piramal Alternatives has fully exited its ₹110 crore investment in Biodeal Pharmaceuticals, achieving an internal rate of return exceeding 20%. The exit follows a period of strong growth for the pharmaceutical firm, which reported significant revenue increases and improved profit margins during the partnership.
Detailed Coverage
Piramal Alternatives has concluded its investment in Biodeal Pharmaceuticals, a company specializing in nasal formulations and pharmaceutical manufacturing. The exit was executed through the full redemption of a ₹110 crore capital injection originally provided by the Piramal Structured Credit Opportunities Fund. According to the firm, this exit generated an internal rate of return, or IRR, of more than 20 percent.
Financial Growth and Operational Discipline
For investors, the exit serves as a case study in how private credit can support mid-sized pharmaceutical companies. During the holding period, Biodeal Pharmaceuticals focused on scaling its manufacturing capacity and tightening its internal governance. The company reported substantial financial growth, with year-on-year revenue increases of 45 percent in FY25 and 60 percent in FY26. These gains were accompanied by better operational efficiency, which helped the company improve its EBITDA margin—a key measure of core business profitability.
Strategic Focus on Pharmaceutical Niches
This investment was part of a broader strategy by Piramal Alternatives to identify companies that operate in specialized segments. By backing Biodeal's expansion into nasal formulation technology, the fund aimed to capitalize on a specific pharmaceutical niche rather than general drug manufacturing. The management teams of both organizations credited the partnership with strengthening Biodeal’s ability to execute large-scale capital projects and improve its market penetration in the healthcare sector.
What This Means for Private Credit Investors
While this is a private transaction rather than a public market event, it highlights the increasing role of structured credit in the Indian pharmaceutical space. Companies like Biodeal often turn to these funds for capital to bypass traditional bank lending constraints while simultaneously upgrading their management and governance frameworks. For observers of the broader healthcare sector, the success of this exit may signal ongoing demand for private capital to fuel growth in specialized manufacturing segments. Investors often look at the successful exits of private credit funds as a proxy for the health of the underlying mid-market corporate sector, specifically in areas where companies are moving toward higher-value products or expanding their production capabilities.